Company Quick10K Filing
Bovie Medical
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 34 $205
10-Q 2019-11-15 Quarter: 2019-09-30
10-Q 2019-08-07 Quarter: 2019-06-30
10-Q 2019-05-08 Quarter: 2019-03-31
10-K 2019-03-14 Annual: 2018-12-31
10-Q 2018-11-02 Quarter: 2018-09-30
10-Q 2018-08-01 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-03-13 Annual: 2017-12-31
10-Q 2017-11-03 Quarter: 2017-09-30
10-Q 2017-08-03 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-10 Annual: 2016-12-31
10-Q 2016-10-27 Quarter: 2016-09-30
10-Q 2016-08-02 Quarter: 2016-06-30
10-Q 2016-05-11 Quarter: 2016-03-31
10-K 2016-03-18 Annual: 2015-12-31
10-Q 2015-11-05 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-08 Quarter: 2015-03-31
10-K 2015-02-27 Annual: 2014-12-31
10-Q 2014-11-10 Quarter: 2014-09-30
10-Q 2014-08-08 Quarter: 2014-06-30
10-Q 2014-05-15 Quarter: 2014-03-31
10-K 2014-03-31 Annual: 2013-12-31
10-Q 2013-11-14 Quarter: 2013-09-30
10-Q 2013-08-14 Quarter: 2013-06-30
10-Q 2013-05-15 Quarter: 2013-03-31
10-K 2013-04-01 Annual: 2012-12-31
10-Q 2012-11-14 Quarter: 2012-09-30
10-Q 2012-08-14 Quarter: 2012-06-30
10-Q 2012-05-15 Quarter: 2012-03-31
10-K 2012-03-29 Annual: 2011-12-31
10-Q 2011-11-14 Quarter: 2011-09-30
10-Q 2011-08-12 Quarter: 2011-06-30
10-Q 2011-05-12 Quarter: 2011-03-31
10-K 2011-03-31 Annual: 2010-12-31
10-Q 2010-11-09 Quarter: 2010-09-30
10-Q 2010-08-09 Quarter: 2010-06-30
10-Q 2010-05-10 Quarter: 2010-03-31
10-K 2010-03-16 Annual: 2009-12-31
8-K 2019-12-03 Other Events, Exhibits
8-K 2019-11-11 Earnings, Exhibits
8-K 2019-10-14 Other Events, Exhibits
8-K 2019-10-14 Other Events, Exhibits
8-K 2019-08-07 Officers, Shareholder Vote, Other Events, Exhibits
8-K 2019-08-07 Earnings, Exhibits
8-K 2019-06-03 Accountant, Exhibits
8-K 2019-05-08 Earnings, Exhibits
8-K 2019-04-26
8-K 2019-04-01 Earnings, Other Events, Exhibits
8-K 2019-03-13 Earnings, Exhibits
8-K 2019-01-23 Enter Agreement
8-K 2019-01-07 Earnings, Exhibits
8-K 2018-12-28 Amend Bylaw, Exhibits
8-K 2018-12-17 Officers, Other Events, Exhibits
8-K 2018-12-12 Other Events, Exhibits
8-K 2018-11-13 Officers, Other Events, Exhibits
8-K 2018-11-01 Earnings, Exhibits
8-K 2018-09-05 Other Events, Exhibits
8-K 2018-08-30 M&A, Officers, Shareholder Vote, Other Events, Exhibits
8-K 2018-08-01 Earnings, Exhibits
8-K 2018-07-09 Enter Agreement, Earnings, Officers, Other Events, Exhibits
8-K 2018-05-14 Earnings, Exhibits
8-K 2018-05-03 Amend Bylaw, Exhibits
8-K 2018-03-14 Officers, Other Events, Exhibits
8-K 2018-03-12 Earnings, Exhibits

Bovie Medical Financials

BVX Metrics, Comps, Filings

Annual | Quarterly

Business

Apyx Medical Corporation ("Company", "Apyx Medical", "we", "us", or "our"), formerly known as Bovie Medical Corporation, was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.

We are a medical technology company and the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue. J-Plasma technology utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision, and minimal invasiveness. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers.

On August 30, 2018, we closed on a definitive asset purchase agreement with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly-owned subsidiary of Symmetry Surgical Inc. ("Symmetry"), pursuant to which we divested and sold our electrosurgical "Core" business segment and related intellectual property, including the Bovie® brand and trademarks, to Symmetry for gross proceeds of $97 million in cash. The divestiture and sale of our Core business segment to Symmetry allows us to further focus on our strategic objective of commercializing our J-Plasma technology, including the RenuvionTM brand in the cosmetic surgery market. We also entered into with Symmetry a transition services agreement, a Patent Licensing Agreement, a Disposables Supply Agreement, and a Generator Manufacturing and Supply Agreement, the latter of which will establish us as an OEM-provider of generators to Symmetry for a period of at least 10 years.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Soliton (SOLY) 229,442 -22.0 -91% 12,755 1,989 0 0 -11,580 -9,928 218,055
Luboa Group (LBAO) 228,780 431.1 50% 1,026 1,413 0 0 513 529 228,187
ENB Financial (ENBP) 227,479 15.1 1% 1,131,645 1,019,131 0 0 10,494 16,552 250,437
Success Entertainment Group (SEGN) 225,300 83% 1,987.8 -1% 910 691 1,300 1,073 -9 113 225,256
Citizens Financial Services (CZFS) 219,700 0% 6.0 1% 1,447,170 1,299,149 6,782 0 18,347 33,786 203,231
Crimson Wine Group (CWGL) 218,161 45% 24.9 0% 246,389 36,244 68,775 31,050 69 9,191 228,512
Isabella Bank (ISBA) 218,022 0% 5.0 1% 1,824,592 1,616,478 5,738 0 14,910 36,569 182,060
Xerium Technologies (XRM) 217,666 10% 22.1 -2% 547,188 698,205 492,202 48,974 -10,514 33,582 743,584
Axcella Health (AXLA) 210,488 -4.6 -21% 122,407 32,463 0 0 -26,020 -25,656 118,578
Powercomm Holdings (PCC) 210,454 19% 142.3 15% 5,177 4,207 13,622 2,647 776 1,478 210,300
Bovie Medical (BVX) 204,586 65% -8.6 -14% 88,883 8,304 21,989 14,236 -12,784 -15,883 137,366
IDEAYA Biosciences (IDYA) 203,897 -8.1 -8% 133,358 12,750 0 0 -10,656 -10,356 83,697
Fuse Enterprises (FSNT) 200,164 86% 128.6 142% 1,099 2 1,016 870 1,555 1,556 200,124
Solbright (SBRT) 195,093 -11% -4.2 -411% 12,978 107,736 3,481 -399 -53,291 -45,982 194,304
Corvus Gold (CORVF) 194,306 -16.7 -110% 10,276 870 0 0 -11,351 -11,351 189,981
Cure Pharmaceutical (CURR) 189,733 69% -8.3 -82% 35,347 25,254 504 350 -28,813 -22,134 182,638
Health Catalyst (HCAT) 187,144 0% -21.3 -8% 139,676 112,251 36,804 0 -10,694 -8,467 180,703
Bicycle Therapeutics (BCYC) 184,557 0% -7.5 -8% 126,246 21,687 1,522 0 -10,217 -10,082 76,021
Technovative Group (TEHG) 182,172 57% -105.6 -33% 5,191 3,101 765 437 -1,719 -1,719 181,597
Acro Biomedical (ACBM) 177,190 10% -1,443.4 -13% 1,081 133 2,916 284 -142 -123 177,189

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash4,8804,1627,9245,7338397797190
Accounts Receivable2,2162,8741,9901,9922,9254,7334,8575,015
Inventory8,1787,9848,4155,7275,9576,1586,5265,212
PP&E7,1767,22912,72913,2956,8106,4496,4085,788
Assets28,24028,18333,17624,83331,44835,11030,98895,610
Accounts Payable1,0858031,0601,5531,2141,6061,5831,423
Long-Term Debt0140140140140
Liabilities6,1235,28811,84620,1398,0448,8878,9567,842
Stockholders' Equity22,11722,89519,0711,50423,40426,22322,03287,768
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue25,41127,67123,66027,68129,52036,62738,88316,686
Cost of Revenue14,68016,33814,46218,68916,96318,71219,1225,893
Gross Profit10,73111,3339,1988,99212,55717,91519,76110,793
R&D1,1971,3291,2601,4162,1602,6182,4552,469
SG&A4,3474,3414,8946,6868,4178,56511,3709,438
Tax-7721700064-156-3,777
Net Income109617-4,339-17,282-5,370-3,950-5,062-9,494
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating1,897165-2,536-417-5,786-2,837-3,704-21,011
Cash Investing-542-753-588-630-921-286-62429,301
Cash Financing-302-1306,886-1,14412,7795,774-179-2,492